As Attached

Credit & Debt View source PDF Explain this filing

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹1356.00

prior close

₹1357.60

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.3%-1.5% vs market

Pharmaceuticals peers, median of 162sector+0.0%-1.3% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Smallcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+0.4

15m

+0.4

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3+0.3-1.5+0.0-1.3

Next day

+0.7+0.3+0.4+0.4+0.2

+1.2-0.1+1.3+0.0+1.2

-1.7-1.6-0.1-0.6-1.1

-0.3-0.4+0.1-0.1-0.2

+9.8-0.3+10.2+0.9+9.0

-1.0+0.2-1.2+0.8-1.8

15d

+0.9+1.9-0.9+1.1-0.2

+1.9+3.3-1.4+2.6-0.7

+7.3+8.6-1.3+6.2+1.1

+1.7+9.7-8.0+9.2-7.5

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

India Ratings and Research (Ind-Ra) has assigned and affirmed credit ratings for bank loan facilities of Eris Therapeutics Limited (ETL), a wholly owned subsidiary of Eris Lifesciences. The agency assigned IND AA/Stable/IND A1+ rating to INR 1,000 million new bank loan facilities and affirmed the same rating for INR 4,200 million facilities (reduced from INR 4,686 million). The ratings reflect strong parent-subsidiary linkages, with ELL providing corporate guarantees for ETL's debt. ETL reported standalone revenue of INR 7,589 million with EBITDA margin of 52% and net leverage of 0.8x in FY25. On a consolidated basis, ELL showed improved credit metrics with net leverage reducing to 2.2x in FY25 from 3.9x in FY24, supported by robust operating performance.

Likely market impact

The stable outlook reflects sustained healthy operating performance and strong credit metrics. The ratings affirm the company's financial stability and may provide comfort to shareholders regarding the subsidiary's debt servicing capability.